REVELATION BIOSCIENCES, INC. financial data

Symbol
REVB, REVBW on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 506% % 182%
Debt-to-equity 27% % -78%
Return On Assets -105% % 29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,720,420 shares 311%
Common Stock, Shares, Outstanding 1,583,969 shares 3539%
Entity Public Float $3,418,594 USD 9.2%
Common Stock, Value, Issued $1,584 USD 3500%
Weighted Average Number of Shares Outstanding, Basic 620,785 shares 4243%
Weighted Average Number of Shares Outstanding, Diluted 620,785 shares 4243%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,063,857 USD 15%
General and Administrative Expense $5,006,957 USD 13%
Operating Income (Loss) $9,070,814 USD -14%
Nonoperating Income (Expense) $157,165 USD 115%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $8,913,649 USD 41%
Earnings Per Share, Basic -23.95 USD/shares 98%
Earnings Per Share, Diluted -23.95 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,700,331 USD 65%
Assets, Current $10,811,628 USD 65%
Property, Plant and Equipment, Net $18,067 USD -68%
Operating Lease, Right-of-Use Asset $722,288 USD
Other Assets, Noncurrent $30,941 USD
Assets $11,582,924 USD 75%
Accounts Payable, Current $577,501 USD -26%
Accrued Liabilities, Current $1,397,644 USD 24%
Liabilities, Current $1,998,158 USD 4.4%
Operating Lease, Liability, Noncurrent $723,771 USD
Liabilities $2,721,929 USD 42%
Retained Earnings (Accumulated Deficit) $49,419,287 USD -22%
Stockholders' Equity Attributable to Parent $8,860,995 USD 88%
Liabilities and Equity $11,582,924 USD 75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,794,407 USD 1.5%
Net Cash Provided by (Used in) Financing Activities $5,417,180 USD -61%
Net Cash Provided by (Used in) Investing Activities $19,172 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 1,583,969 shares 3539%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,700,331 USD 65%
Deferred Tax Assets, Valuation Allowance $17,561,165 USD 18%
Deferred Tax Assets, Gross $17,561,165 USD 18%
Operating Lease, Liability $746,784 USD
Depreciation $28,882 USD 15%
Payments to Acquire Property, Plant, and Equipment $19,172 USD
Lessee, Operating Lease, Liability, to be Paid $881,855 USD 8142%
Property, Plant and Equipment, Gross $117,055 USD -23%
Operating Lease, Liability, Current $23,013 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $406,220 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $93,052 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $135,071 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $382,583 USD
Deferred Tax Assets, Operating Loss Carryforwards $14,378,580 USD 31%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $58,278,698 USD 29%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $595,368 USD 253%